ISRCTN34273159进行中（未招募）未知
Early detection of bladder cancer in Yorkshire: feasibility assessments for implementing a targeted study in populations with high disease-specific mortality risk
niversity of Sheffield0 个研究点目标入组 1,311 人开始时间: 2022年6月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,311
研究概览
简要总结
2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37678944/ (added 08/09/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Men and women
- •2. Aged 55 – 80 years
- •3. Participants already enrolled within the YLST
- •4. Registered with a GP within the Leeds CCG area
- •5. Consented to contact from other research teams at the second YLST Lung Health Check visit
- •1. Men aged 65-79 years
- •2. Registered with a GP Practice identified as being in a region with a high bladder cancer mortality risk
- •1. Men and women aged 65-79 years referred to a recruiting urological department under the 2WW pathway for the investigation of haematuria (to include cystoscopy and urinary tract ultrasound, ± CT urogram)
排除标准
- •Current exclusion criteria as of 15/07/2022:
- •1. Unable to/did not consent to contact from other research teams
- •2. Insufficient capacity to give consent to take part in the research as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment.
- •1. National Data Opt-outs
- •2. Ever diagnosis of bladder or kidney cancer
- •3. Diagnosis with any other cancer within the past 5 years (except non-malignant skin cancer)
- •4. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions coded in GP records:
- •4.1. Dementia
- •4.2. Alzheimer’s disease
- •4.3. Parkinson’s disease
- •or as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment
- •1. Unable to provide written informed consent
- •2. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions in medical notes:
- •2.1. Dementia
- •2.2. Alzheimer’s disease
- •2.3. Parkinson’s disease
- •or as determined by the investigator/person taking consent at the 2WW appointment
- •3. Evidence in patient medical record of historic dissent to use of data in research
- •4. Participant has opted out of data use via the National Data Opt Out
- •Previous exclusion criteria:
- •1. Unable to/did not consent to contact from other research teams
- •2. Insufficient capacity to give consent to take part in the research as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment.
- •1. National Data Opt-outs
- •2. Ever diagnosis of bladder or kidney cancer
- •3. Diagnosis with any other cancer within the past 5 years (except non-malignant skin cancer)
- •4. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions coded in GP records:
- •4.1. Dementia
- •4.2. Alzheimer’s disease
- •4.3. Parkinson’s disease
- •or as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment
- •1. Unable to provide written informed consent
- •2. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions in medical notes:
- •2.1. Dementia
- •2.2. Alzheimer’s disease
- •2.3. Parkinson’s disease
- •or as determined by the investigator/person taking consent at the 2WW appointment
研究者
相似试验
尚未招募
不适用
Diagnosis of bladder cancer using probe-based confocal laser endomicroscopyBladder CancerJPRN-UMIN000021067Depatment of Urology, Kyoto Prefectural University of Medicine50
已完成
3 期
Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence CystoscopyBladder CancerNCT00233402Photocure789
已完成
不适用
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy UnitUrinary Bladder NeoplasmsNCT06281691Jørgen Bjerggaard Jensen127
进行中（未招募）
不适用
rinary Xpert bladder cancer detection test in patients with haematuriaSuspected bladder cancerMalignant neoplasm of bladderCancerISRCTN40815027niversity of Dundee600
已完成
不适用
Bladder Cancer Prognosis Programme (incorporating SELENIB trial)BCPP - bladder cancer (superficial and invasive)SELENIB - superficial bladder cancerBladder cancerCancerISRCTN13889738niversity of Birmingham (United Kingdom)270